当前位置： SCI文献检索 > CANCER CHEMOTHERAPY AND PHARMACOLOGY期刊下所有文献 > Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer.

Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer.

Abstract：

PURPOSE:To evaluate the safety and efficacy of the combination of cisplatin on day 1 and docetaxel on days 1, 8 and 15 every 4 weeks for the treatment of previously untreated patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:A group of 38 patients with advanced or metastatic NSCLC who had not received prior treatment and who were aged under 75 years were enrolled. The patients received intravenous infusions of docetaxel (25 mg/m2, days 1, 8, 15) and cisplatin (80 mg/m2, day 1), followed by a week of rest. RESULTS:Six patients had grade 3/4 neutropenia (18%), but there were no episodes of neutropenic fever. Nonhematologic toxicities were also mild. There were 12 partial responses for an objective response rate of 31.6%. The median survival was 11.8 months, and the 1-year survival rate was 46.5%. CONCLUSION:Cisplatin combined with weekly administration of docetaxel is efficacious against NSCLC with low hematotoxicity, and this schedule may be an alternative for the treatment of NSCLC.

journal_name

Cancer Chemother Pharmacol

journal_title

Cancer chemotherapy and pharmacology

authors

Tsunoda T,Koizumi T,Hayasaka M,Hirai K,Koyama S,Takabayashi Y,Fujimoto K,Kubo K

doi

10.1007/s00280-004-0810-5

keywords:

subject

Has Abstract

pub_date

2004-08-01 00:00:00

pages

173-7

issue

2

eissn

0344-5704

issn

1432-0843

journal_volume

54

pub_type

临床试验,杂志文章

相关文献

CANCER CHEMOTHERAPY AND PHARMACOLOGY文献大全
  • Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells.

    abstract：:Dihydroartemisinin (DHA), a more water-soluble active metabolite of artemisinin derivatives, is safe and the most effective antimalarial analog of artemisinin. In the present investigation, we assessed the effect of DHA on vascular endothelial growth factor (VEGF) expression and apoptosis in chronic myeloid leukemia (...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-005-0002-y

    authors： Lee J,Zhou HJ,Wu XH

    更新日期：2006-01-01 00:00:00

  • Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.

    abstract：PURPOSE:The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects. METHODS:Six subjects received a single oral dose of 800 mg ¹⁴C-sonidegib (74 kBq, 2.0 µCi) under fasting conditions. Blood, plasma, urine, and fecal samples wer...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-014-2468-y

    authors： Zollinger M,Lozac'h F,Hurh E,Emotte C,Bauly H,Swart P

    更新日期：2014-07-01 00:00:00

  • New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models.

    abstract：:A group of folate analogs of the 10-deaza-aminopterin series, which were designed on the basis of the results of an intensive biochemical and pharmacokinetic program, have been examined in therapy experiments utilizing a group of murine tumor models. These new analogs were found to be markedly superior to methotrexate...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：

    authors： Sirotnak FM,DeGraw JI,Schmid FA,Goutas LJ,Moccio DM

    更新日期：1984-01-01 00:00:00

  • Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.

    abstract：PURPOSE:Triple-negative breast cancer (TNBC) is an aggressive, lethal, and heterogeneous subtype of breast cancers, tending to have lower 5-year survival rates than other BC subtypes in response to conventional chemotherapies. This study's aim was to identify advanced regimens to effectively control TNBC tumor developm...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-019-04013-y

    authors： Pattarawat P,Wallace S,Pfisterer B,Odoi A,Wang HR

    更新日期：2020-01-01 00:00:00

  • A phase I study of resminostat in Japanese patients with advanced solid tumors.

    abstract：PURPOSE:This study was performed to evaluate the safety and determine the recommended dose (RD) of resminostat monotherapy, an oral histone deacetylase (HDAC) inhibitor, in Japanese patients with advanced solid tumors. METHODS:Resminostat was administered to patients with advanced solid tumors on a 14-day cycle consis...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-015-2741-8

    authors： Kitazono S,Fujiwara Y,Nakamichi S,Mizugaki H,Nokihara H,Yamamoto N,Yamada Y,Inukai E,Nakamura O,Tamura T

    更新日期：2015-06-01 00:00:00

  • In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time.

    abstract：PURPOSE:The effect of an anticancer treatment on tumor cell proliferation in vitro can be described as a three-dimensional surface where the inhibitory effect is related to drug concentration and treatment time. The analysis of this kind of response surface could provide critical information: for example, it could indi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-003-0688-7

    authors： Germani M,Magni P,De Nicolao G,Poggesi I,Marsiglio A,Ballinari D,Rocchetti M

    更新日期：2003-12-01 00:00:00

  • Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex.

    abstract：:The effect of 7-alkyl substitutions on growth inhibition in seven Camptothecin (CPT) ring systems with various groups at the ten position was evaluated in three human breast cancer cell lines that model (1) hormone-sensitive (MCF-7/wt), (2) hormone insensitive (MDA-MB-231), or (3) alkylator-resistant (MCF-7/4-hc) form...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-005-0007-6

    authors： Adams DJ,da Silva MW,Flowers JL,Kohlhagen G,Pommier Y,Colvin OM,Manikumar G,Wani MC

    更新日期：2006-01-01 00:00:00

  • Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates.

    abstract：UNLABELLED:Hypericin, a polycyclic aromatic dianthroquinone, is a natural pigment derived from the plant Hypericum perforatum (St John's Wort). The compound has been synthesized and shown to inhibit the growth of malignant glioma cell lines in vitro via inhibition of protein kinase C. Oral hypericin has entered clinica...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800000188

    authors： Fox E,Murphy RF,McCully CL,Adamson PC

    更新日期：2001-01-01 00:00:00

  • The antitumor effects of human lymphoblastoid interferon on human renal cell carcinoma in athymic nude mice.

    abstract：:The antitumor effects of human lymphoblastoid interferon (HLBI) on human renal cell carcinomas transplanted in nude mice, i.e., KU-2 and RCC-1, were investigated and compared with those on other human tumors, viz. HeLa (cervical carcinoma), KB (nasopharyngeal carcinoma), H.Ep#2 (laryngeal carcinoma), and MX-1 (breast ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00258113

    authors： Yamaoka T,Takada H,Yanagi Y,Kataoka T,Sakurai Y

    更新日期：1985-01-01 00:00:00

  • Pharmacokinetic study of fludarabine phosphate (NSC 312887).

    abstract：:Characterization of the pharmacokinetics of 2-FLAA has been completed in seven patients receiving 18 or 25 mg/m2 daily X 5 of 2-FLAMP over 30 min. Assuming 2-FLAMP was instantaneously converted to 2-FLAA, the plasma levels of 2-FLAA declined in a biexponential fashion. Computer fitting of the plasma concentration-time...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00256699

    authors： Hersh MR,Kuhn JG,Phillips JL,Clark G,Ludden TM,Von Hoff DD

    更新日期：1986-01-01 00:00:00

  • Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.

    abstract：PURPOSE:Although cisplatin is the drug of choice in treating lung cancer patients, relapse and resistance is a common drawback to its clinical effectiveness. Based on cisplatin's reported ability to interfere with numerous cellular components, including mitochondria, we probed alterations in metabolism in cisplatin-res...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-013-2366-8

    authors： Sullivan EJ,Kurtoglu M,Brenneman R,Liu H,Lampidis TJ

    更新日期：2014-02-01 00:00:00

  • Comparative brain tissue distribution of camptothecin and topotecan in the rat.

    abstract：PURPOSE:The primary objective of this investigation was to compare the extent of brain distribution of the lactone and the carboxylate forms of camptothecin (CPT) and topotecan (TPT) in awake freely moving rats. METHODS:The plasma concentration-time profiles of the lactone and the carboxylate forms of CPT and TPT were...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050908

    authors： El-Gizawy SA,Hedaya MA

    更新日期：1999-01-01 00:00:00

  • Phase II study of teniposide in adenocarcinoma of the lung.

    abstract：:A total of 26 evaluable patients with previously untreated, non-resectable adenocarcinoma of the lung were given 80 mg/m2 i.v. teniposide daily for 5 days every 3 weeks. Three partial responses (11%) were obtained that lasted for 12, 11 and 32 weeks, respectively. Leucopenia was the dose-limiting side effect, with WBC...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00685166

    authors： Sørensen JB,Bach F,Dombernowsky P,Hansen HH

    更新日期：1991-01-01 00:00:00

  • Potentiation of antitumor activity of 1-phthalidyl 5-fluorouracil by acetazolamide.

    abstract：:The effect of acetazolamide (A.A.) on the antineoplastic activity of 1-phthalidyl 5-fluorouracil (PH-FU) against rat and mouse solid tumors was examined. A.A., an inhibitor of liver PH-FU hydrolase, had no antitumor activity but greatly enhanced the activity of PH-FU when coadministered. The potentiation was evaluated...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00255286

    authors： Kasai H,Tonda K,Hirata M

    更新日期：1986-01-01 00:00:00

  • Antitumor activity of halogen analogs of phosphoramide, isophosphoramide, and triphosphoramide mustards, the cytotoxic metabolites of cyclophosphamide, ifosfamide, and trofosfamide.

    abstract：:A series of halogen analogs of phosphoramide mustard, isophosphoramide mustard, and triphosphoramide mustard, the cytotoxic metabolites of the antitumor drugs cyclophosphamide, ifosfamide, and trofosfamide, respectively, was evaluated in vitro against human tumor cell lines and in vivo against experimental tumors to i...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00685076

    authors： Struck RF,Schmid SM,Waud WR

    更新日期：1994-01-01 00:00:00

  • High-dose chemotherapy with hematopoietic rescue in breast cancer: from theory to practice.

    abstract：:The development of more effective treatment strategies currently provides the only realistic hope of reducing breast cancer mortality. Among such treatments, high-dose chemotherapy (HDC) has been proposed to be a potentially curative strategy. Consideration of the factors involved in the successful treatment of human ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,评审

    doi：10.1007/s002800051067

    authors： Bezwoda WR

    更新日期：1997-01-01 00:00:00

  • Cellular pharmacology of D-3-azido-3-deoxy-myo-inositol, an inhibitor of phosphatidylinositol signaling having antiproliferative activity.

    abstract：:D-3-Azido-3-deoxy-myo-inositol (3AMI) is an inhibitor of the growth of v-sis-transformed NIH 3T3 cells but not of wild-type NIH 3T3 cells, whose effects may be mediated through the phosphatidylinositol-3'-kinase pathway. We studied some properties of the cellular pharmacology of 3AMI using high-specific-activity [3H]-...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00686287

    authors： Brunn G,Fauq AH,Chow S,Kozikowski AP,Gallegos A,Powis G

    更新日期：1994-01-01 00:00:00

  • Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract.

    abstract：PURPOSE:Little information is available about changes in renal function after cisplatin-based chemotherapy (CBCT) in patients with a solitary kidney. The authors evaluated the renal safety and efficacy of CBCT after nephroureterectomy for upper urinary tract-urothelial carcinoma (UUT-UC). METHODS:The data of patients ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1349-2

    authors： Cho KS,Joung JY,Seo HK,Cho IC,Chung HS,Chung J,Lee KH

    更新日期：2011-04-01 00:00:00

  • Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer.

    abstract：PURPOSE:Following a previously published pre-clinical validation, this phase I study evaluated the safety, maximum tolerated dose, anti-tumour activity and immune status of a gemcitabine-chloroquine combination as a first- or late-line treatment in patients with metastatic or unresectable pancreatic cancer. METHODS:In...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-017-3446-y

    authors： Samaras P,Tusup M,Nguyen-Kim TDL,Seifert B,Bachmann H,von Moos R,Knuth A,Pascolo S

    更新日期：2017-11-01 00:00:00

  • In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents.

    abstract：PURPOSE:Artemisinins are now established drugs for treatment of malaria. These agents have been shown to possess impressive anti-cancer properties. We have investigated the role of artemisone (ATM), a novel derivative of artemisinin (ART) in a cancer setting both alone and in combination with established chemotherapeut...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1355-4

    authors： Gravett AM,Liu WM,Krishna S,Chan WC,Haynes RK,Wilson NL,Dalgleish AG

    更新日期：2011-03-01 00:00:00

  • Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents.

    abstract：PURPOSE:The present study was designed to determine pharmacological and biochemical properties of 2-methoxyantimycin A analogs (OMe-A1, OMe-A2, OMe-A3, and OMe-A5), which are novel antitumor compounds, and provide a basis for future pharmaceutical development, preclinical evaluation, and clinical trials. METHODS:A hig...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-004-0978-8

    authors： Wang H,Li M,Rhie JK,Hockenbery DM,Covey JM,Zhang R,Hill DL

    更新日期：2005-09-01 00:00:00

  • Dependence on PI3K/Akt signaling for malignant rhabdoid tumor cell survival.

    abstract：PURPOSE:Malignant rhabdoid tumors (MRT), although rare, are one of the most aggressive pediatric malignancies. Loss of INI1, a tumor suppressor gene and member of the SWI/SNF chromatin remodeling complex, is a recurrent genetic characteristic of these tumors and an important diagnostic marker. We have previously demons...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-008-0796-5

    authors： Foster K,Wang Y,Zhou D,Wright C

    更新日期：2009-04-01 00:00:00

  • Tumor microenvironment promotes breast cancer chemoresistance.

    abstract：:Breast cancer is presently the most predominant tumor type and the second leading cause of tumor-related deaths among women. Although advancements in diagnosis and therapeutics have momentously improved, chemoresistance remains an important challenge. Tumors oppose chemotherapeutic agents through a variety of mechanis...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,评审

    doi：10.1007/s00280-020-04222-w

    authors： Mehraj U,Dar AH,Wani NA,Mir MA

    更新日期：2021-01-09 00:00:00

  • A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients.

    abstract：:Cyclophosphamide demonstrates enhanced tumoricidal activity with decreased bone marrow toxicity when given on a divided-dose schedule in certain animal models. A total of 22 patients presenting with refractory metastatic cancer were treated in a phase I trial of continuous infusion of cyclophosphamide over 96 h. Granu...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00686337

    authors： Eder JP,Elias AD,Ayash L,Wheeler CA,Shea TC,Schnipper LE,Frei E 3rd,Antman KH

    更新日期：1991-01-01 00:00:00

  • Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas.

    abstract：PURPOSE:Sarcomas are a rare and heterogeneous variant of cancer. The standard of care treatment involves surgical resection with radiation in high-risk patients. Despite appropriate treatment approximately 50 % of patients will suffer and die from recurrent disease. The purpose of this article is to review the current ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s00280-016-3055-1

    authors： Nathenson MJ,Sausville E

    更新日期：2016-11-01 00:00:00

  • Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.

    abstract：PURPOSE:Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib to induce apoptosis. ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-012-1839-5

    authors： Bose P,Perkins EB,Honeycut C,Wellons MD,Stefan T,Jacobberger JW,Kontopodis E,Beumer JH,Egorin MJ,Imamura CK,Douglas Figg W Sr,Karp JE,Koc ON,Cooper BW,Luger SM,Colevas AD,Roberts JD,Grant S

    更新日期：2012-06-01 00:00:00

  • Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone.

    abstract：:A 44-year-old man who had achieved a complete remission of malignant peritoneal mesothelioma after the intraperitoneal administration of 25 mg/m2 mitoxantrone presented with clinical and radiological signs of intestinal obstruction suggestive of recurrent disease at about 2 years following the initial treatment. Howev...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00686012

    authors： Vlasveld LT,Taal BG,Kroon BB,Gallee MP,Rodenhuis S

    更新日期：1992-01-01 00:00:00

  • A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.

    abstract：PURPOSE:Seviteronel is an orally-administered selective cytochrome P450c17a 17,20-lyase and androgen receptor inhibitor with anti-tumor activity in vitro and in vivo, and clinical activity in men with advanced castration-resistant prostate cancer (CRPC) and men and women with advanced breast cancer. The purpose of this...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-019-03908-0

    authors： Peer CJ,Schmidt KT,Kindrick JD,Eisner JR,Brown VV,Baskin-Bey E,Madan R,Figg WD

    更新日期：2019-10-01 00:00:00

  • Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man.

    abstract：:In five cancer patients we have determined the pharmacokinetics of 4'-deoxydoxorubicin (4'-DOX), its alcoholic metabolite 4'-deoxydoxorubicinol and the occurrence of circulating 7-deoxyaglycone metabolites. The 7-deoxyaglycone of the alcohol metabolite, the major aglycone of Adriamycin (ADR) present in man, was not de...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00570499

    authors： Cummings J,Kerr DJ,Kaye SB

    更新日期：1987-01-01 00:00:00

  • Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.

    abstract：PURPOSE:Topotecan is widely used for refractory solid tumors but multi-drug resistance may occur due to tumor expression of ATP-binding cassette (ABC) transporters. Since erlotinib, an inhibitor of the epidermal growth factor receptor, also inhibits several ABC transporters, we performed a phase I study to evaluate the...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-014-2385-0

    authors： Stewart CF,Tagen M,Schwartzberg LS,Blakely LJ,Tauer KW,Smiley LM

    更新日期：2014-03-01 00:00:00